Form 4: Amylyx CMO Sells Shares for Tax Obligations

Amylyx Pharmaceuticals' Chief Medical Officer, Camille L. Bedrosian, sold 6,580 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Camille L. Bedrosian, Chief Medical Officer of Amylyx Pharmaceuticals, Inc. (AMLX), reported a sale of common stock.
• The transaction occurred on December 1, 2025, and involved the disposition of 6,580 shares.
• The shares were sold at a weighted average price of $14.3493 per share, with prices ranging from $14.30 to $14.42.
• The sale was non-discretionary and executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Ms. Bedrosian beneficially owns 175,756 shares of Amylyx Pharmaceuticals common stock directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating it was pre-arranged.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale of shares to cover tax obligations related to restricted stock unit vesting, which is a common occurrence for executives and does not indicate a change in sentiment towards the company.

Positives

• The sale was automatic and non-discretionary, solely for tax withholding purposes, not indicating a lack of confidence by the insider.
• The Chief Medical Officer retains a significant beneficial ownership of 175,756 shares after the transaction.

Negatives

• The direct beneficial ownership of common stock by a key executive has slightly decreased by 6,580 shares.

Future Outlook

N/A

Management Comments

• The sale of shares was required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.
• Such sales were automatic and not at the discretion of the Reporting Person.

Industry Context

N/A

Stakeholder Impact

• Shareholders may note a slight reduction in direct insider ownership, but the non-discretionary nature of the sale suggests no change in management's confidence or strategic direction.

Key Dates

Recommendation

The reported transaction is a non-discretionary sale of shares by the Chief Medical Officer solely to satisfy tax withholding obligations upon the vesting of restricted stock units. This is a common and expected event for executives receiving equity compensation and does not reflect a change in the officer's confidence in the company or its future prospects. Therefore, it does not warrant a change in investment recommendation based on this filing alone.

Keywords

Amylyx Pharmaceuticals, AMLX, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Camille L. Bedrosian, Chief Medical Officer